Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: July 2010

31 07, 2010

Cross Reference Drug Interactions Using These Two Online Programs

Tags: , , , |1 Comment

Last week a reader e-mailed me, looking for a way to cross reference drug interactions.  There are a number of interactive programs available on the Internet which do just that.  Here is one I have used:  Medscapes's Drug Interaction also has one.  Name is the same but it works a bit differently: Drug

30 07, 2010

Link To Myeloma Beacon Story About Improving Survival Rates For Multiple Myeloma Patients

Tags: , , , , |3 Comments

Here is the first part of a story which ran Wednesday in The Myeloma Beacon:Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma PatientsBy Michelle Spektor - Published July 28, 2010A statistical analysis of two Phase 3 trials found relapsed and refractory multiple myeloma patients who achieved complete remission

26 07, 2010

Monday Morning Press Conference Notes About Phase 2 Trial Results For Onyx Pharmaceutical’s New Anti-Myeloma Drug, Carfilzomib

Tags: , , , , , |0 Comments

I just concluded attending an online press conference with officials from Onyx Pharmaceuticals, manufacturers of the experimental anti-myeloma drug, carfilzomib.This was primarily a business related press conference, especially the Q & A portion at the end. Since journalists weren't presented a written transcript, I will keep the details basic. You can expect a follow-up soon

25 07, 2010

New Pomalidomide Study Available To Multiple Myeloma Patients Who’s Revlimid Has Stopped Working

Tags: , , , , , , , |0 Comments

Since it may be two or three years until Celgene's oral anti-myeloma novel therapy agent, pomalidomide, is approved by the FDA and widely available, patients with relapsed and/or refractory multiple myeloma may want to consider getting involved in a pomalidomide related clinical study.If you have tried Revlimid and it is no longer working you may

23 07, 2010

Read More About The Faces Of Multiple Myeloma

Tags: , |0 Comments

I write a column for The Myeloma Beacon every Thursday.  This week's column focuses on Cathy Grant, Dr. Lee Green and a program called Moffitt Diversity.  Moffitt Cancer Center is located on the north edge of Tampa, Florida, and adjoins the University of South Florida campus.  The Moffitt Diversity program was designed to help previously

22 07, 2010

Carfilzomib Update: Onyx Pharmeceuticals Announces Start Of New Phase 3 Trial Combining Carfilzomib With Revlimid

Tags: , , |3 Comments

Yesterday I received an e-mail requesting an update on carfilzomib.  Perfect timing!  This press release announcing the start of a new Phase 3 carfilzomib combo trial arrived last night.  The release gives a summary review of completed and ongoing carfilzomib trials: Onyx Pharmaceuticals Initiates Phase 3 Carfilzomib Combination Trial in Relapsed Multiple Myeloma Emeryville, CA

20 07, 2010

Even The Associated Press Makes Mistakes!

Tags: , , |0 Comments

Thursday I quoted the Associated Press (AP) in a story I did about a new anti-myeloma drug, perifosine.  You would have had to read it very carefully, but AP is admiting it made a mistake which is good news for multiple myeloma patients.  NEW YORK   Correction: Keryx's perifosine drug storyIn a story July 14 about Keryx Biopharmaceuticals, The Associated

20 07, 2010

Targeting Genes Controled By Polycomb Repressor Complex (PcG) May Help Control Multiple Myeloma

Tags: , |0 Comments

I'm finding results of this study all over the Internet.  Way too early to tell if researchers have uncovered something which will really help:Researchers from Uppsala University have now presented a conceptually new model for the development and progression of multiple myeloma- one of the most common blood cancers, and at present considered to be

19 07, 2010

Post Stem Cell Transplant Maintenance Therapy Delays Multiple Myeloma Relapse In A Majority Of Patients

Tags: , , , , , |3 Comments

One more stem cell transplant (SCT) follow-up point and story.  Medscape Medical News posted an article, Lenalinomide Maintenance Halves Multiple Myeloma Relapse, written by Zosia Chustecka just before the ASCO meetings this spring:May 26 2010 — Patients with multiple myeloma who were treated with high-dose chemotherapy and autologous stem cell transplantation and then went on

17 07, 2010

Is A Stem Cell Transplant The Best Anti-Multiple Myeloma Therapy After First Relapse?

Tags: , , , , , |2 Comments

Yesterday I began to describe the anti-myeloma strategy I expect to use once my multiple myeloma returns. As my myeloma slowly (very slowly, thank God!) begins to creep back, I am facing a number of important choices. Do I increase my Revlimid dose and frequency—then add dex to try and knock the cancer back again?

16 07, 2010

Stem Cell Transplants Still A Viable Option For Multiple Myeloma Patients–Especially Later In Their Treatment Cycle

Tags: , , , |0 Comments

Monday I wrote an article about a research study, presented at ASCO titled, Is It Time to Abandon Up-Front Transplantation in Multiple Myeloma? Here is a comment I recieved from a reader who calls himself "J" the next day: Pat, there is no answer yet for this question. I am so glad I did transplant. Two

15 07, 2010

Perifosine Continues To Show Strong Anti-Cancer Results: Multiple Myeloma Perifosine Update

Tags: , , , |0 Comments

Keryx's perifosine gets second orphan drug status(AP) – 10 hours agoNEW YORK — Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children...Perifosine also has orphan drug status as a colorectal cancer treatment,

15 07, 2010

New British Anti-Myeloma Drug Study Shows Promise

Tags: , |0 Comments

Here is a link to a British study abstract about another new, anti-myeloma drug:EntreMed’s ENMD-2076 Demonstrates Significant Anti-Cancer Activity in Multiple Myeloma Preclinical Models.The study results were published in the British Journal of Haematology.ENMD-2076 is another variation of a kinase inhibitor.  Lots of research going on worldwide using kinase inhibitors against multiple myeloma.  Hopefully some